ALTERATIONS IN ENDOTHELIAL CELL METABOLISM DURING HEART TRANSPLANT REJECTION

心脏移植排斥期间内皮细胞代谢的变化

• 批准号: 6280756
• 负责人: JAMES H REVKIN
• 金额: --
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-02-18 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6280756
• 关键词: Mammalia; bioengineering /biomedical engineering; biomedical resource; cardiovascular system; human tissue; technology /technique; transplantation

Heart transplantation is now an acceptable treatment alternative for select patients with end-stage heart disease. The five year survival for transplant recipients is over 70%. Unfortunately up to 40% of these transplant recipients will develop transplant coronary artery disease, a vasculopathy which is diffuse but generally remains undetected until its late states. It may be a form of chronic vascular rejection and when present, ultimately results in left ventricular dysfunction and failure of the graft. The investigators plan to test the hypothesis that vascular tissue, in particular endothelial cells, will reveal abnormalities in metabolism during heart transplant rejection, despite preserved coronary perfusion. The multiple indicator dilution technique will be used to assess adenosine uptake in an isolated rat heterotopic heart transplant preparation. The investigators will compare the endothelial adenosine flux in control syngeneic heart allografts to that of allogeneic rejecting heart allografts. Adenosine flux will also be assessed in a group of allogeneic heterotopic heart transplants from rats treated with cyclosporine and methylprednisolone.

心脏移植现在是一种可接受的治疗选择 针对特定的终末期心脏病患者 五年 移植受者的存活率超过70%。 不幸的是， 这些移植受者中有40%将发展为移植冠状动脉 动脉疾病，一种弥漫性血管病变，但通常仍 直到晚期才被发现 这可能是一种慢性的 当出现血管排斥反应时，最终导致左 心室功能障碍和移植物衰竭。 调查人员 计划检验一个假设，即血管组织，特别是 内皮细胞，将揭示代谢异常， 心脏移植排斥反应，尽管保留了冠状动脉灌注。 的 将使用多指示剂稀释技术评估腺苷 在分离的大鼠异位心脏移植制剂中的摄取。 研究人员将比较内皮细胞腺苷流量， 同种异体心脏移植与同种异体排斥反应的对照 心脏移植 腺苷通量也将在一组 大鼠同种异体异位心脏移植 环孢霉素和甲基强的松龙。